Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ( "Entheon" or the "Company" ), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, announces that it is proceeding on a non-brokered private... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ( "Entheon" or the "Company" ), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to announce that its expanded psychedelics genetic... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, today announced that the first patient has been enrolled in... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to provide an update on its Observational Study, EBIQ-101. We are pleased to report that the first patient has been dosed in EBIQ-101, a study using... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is launching the upcoming EBIQ-101 Observational Trial (" EBIQ-101 " or... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, announced today the approval by the local Dutch ethics committee of EBRX-101, a comprehensive phase I clinical trial evaluating the pharmacokinetics,... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, has announced an agreement with Psychedelics Today, LLC ( "Psychedelics Today'' ) to help drive brand awareness of the Company's Psychedelics Genetic Test Kit,... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company ") announced that it has filed a preliminary short form base shelf prospectus dated January 14, 2022 (the " Preliminary Prospectus ") with the securities commissions in each of the provinces and territories of Canada. The Preliminary Prospectus has not yet become final for the purpose of the sale of securities. Once the receipts for... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, has announced the submission of the regulatory package for its upcoming Phase 1 Clinical trial, EBRX-101, to the ethics committee of the BEBO Foundation for the... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ( "Entheon" or the "Company" ), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to announce that its expanded psychedelics genetic testing panel, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc. ( "HaluGen" ), is... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to provide an update on its patent portfolio as well as nonclinical and clinical programs. US Provisional Patent Filed In furtherance of its program,... Read More

Eric Sprott announces that, today, 600,000 common share purchase warrants (Warrants) of Entheon Biomedical Corp. , (held by 2176423 Ontario Ltd., a corporation he beneficially owns) expired unexercised representing a decrease in holdings of approximately 4.2% of the outstanding common shares (Shares) on a partially diluted basis since the date of the last early warning report. Prior to the expiry of these Warrants, Mr.... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to announce that Timothy Ko, Entheon's Chief Executive Officer, will be presenting at the 2nd Annual H.C. Wainwright Psychedelics Conference being held... Read More

Entheon Biomedical (CSE: ENBI) will be presenting at the Benzinga Global Small Cap Conference taking place on December 8-9, 2021. We invite our shareholders and all interested parties to explore investment opportunities within the global small cap space. Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/december-2021-global/ About the Benzinga Global Small Cap Conference The... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to announce that Dr. Henry Kranzler, Professor of Psychiatry and Director of the Center for Studies of Addiction at the University of Pennsylvania's... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to provide an update on its upcoming human trial, EBRX-101 and on nonclinical DMT initiatives. Clinical Trial Update The Company announces today that GMP DMT drug product has shipped from Ofichem Laboratorium to CHDR's partner... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced today that recruitment has begun for the clinical research study with Heading Health LLC ( "Heading Health" ) as institution and Dr. Steve Levine, MD, as principal investigator to determine the electro-neurophysiologic effects of... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to provide an update on its operations and progress on its strategic initiatives. Observational Study Update Entheon is pleased to announce that its observational study assessing the neurophysiological effects of ketamine is... Read More

Microdose Psychedelic Insights is proud to announce the upcoming Psychedelic Capital: September 2021 conference to be taking place on September 30, 2021, starting at 1:30pm EDT. The September edition will engage in discussions on Novel Psychedelic Molecules and Women in Psychedelics: Exploring the role of research and therapeutic experiences . The conference will play host to a number of corporate presentations, including... Read More

Microdose in partnership with Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, Small Pharma (TSXV: DMT) a neuropharmaceutical company taking a novel approach to depression drug development, Algernon Pharmaceuticals Inc. (CSE: AGN) a clinical-stage drug development company focused on the disease areas of stroke, idiopathic... Read More

Microdose Psychedelic Insights , a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, will be hosting the upcoming DMT Conference in an entirely virtual format Sept. 9-10, 2021. The virtual event will explore the potential of DMT (“Dimethyltryptamine”) at the intersection of drug development and... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that Dr. David Erritzoe, the current Clinical Director of the Imperial College's Center for Psychedelic Research, has been appointed to Entheon's Advisory Board. Dr. Erritzoe has significant experience in psychiatry,... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company ("DTC") in the United States. The DTC is the largest securities depository in the world and facilitates... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, today announced the sponsorship of a clinical research study with Heading Health LLC ( "Heading Health" ) as institution and Dr. Steve Levine, MD, as principal investigator to determine the electroneurophysiologic effects of ketamine. Entheon... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company ") is pleased to announce that the Company completed its acquisition of Lobo Genetics Inc. (" Lobo "), a personalized genetics company with a direct-to-consumer platform currently being used in both the psychedelics and cannabis spaces to provide personalized insights into an individual's response to hallucinogenic and psychoactive... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of Dr. Andrew (Andy) Greenshaw, Professor of Psychiatry and Neuroscience and Associate Chair (Research) for Psychiatry at the University of Alberta. Dr. Greenshaw is a Fellow of the Royal Society of Arts; a... Read More

Microdose in partnership with Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, Algernon Pharmaceuticals Inc. (CSE: AGN) a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and COVID-19, and Pharmadrug , a Biotech Company Focused on the R&D... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of emergency physician and addiction specialist, Dr. Dinesh Bayana as a medical advisor, providing expertise on the development of the Company's DMT clinical program as it relates to patient care in the... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ( "Entheon" or the "Company" ), a biotechnology company focused on developing psychedelic medicines to treat addiction, has announced an agreement with Maya health PBC ( "Maya'' ) to help drive brand awareness of the Company's Psychedelics Genetic Test kit, developed and commercialized by its wholly-owned subsidiary HaluGen Life Sciences Inc. ("HaluGen"). Maya... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, has announced an agreement with 3W Wellness Inc. ( "Third Wave'' ) to help drive brand awareness of the company's Psychedelics Genetic Test kit, developed and commercialized by wholly-owned subsidiary HaluGen Life Sciences Inc. ("HaluGen"). The... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ( "Entheon" ), a biotechnology company focused on developing psychedelic medicines to treat addiction, and Silo Wellness Inc. (CSE: SILO) (OTC: SILFF) (FSE:3K70) ( "Silo Wellness"), a functional and psilocybin mushroom company and psychedelic wellness retreats operator, have signed a referral agreement (the "Agreement" ), to help drive brand awareness of the... Read More

TORONTO, June 17, 2021 (GLOBE NEWSWIRE) -- Silo Wellness Inc. (“ Silo Wellness ” or “the Company ”) (CSE: SILO) (FRA: 3K70) (OTC: SILFF), a functional and psilocybin mushroom company offering psychedelic wellness retreats, and Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon "), a biotechnology company focused on developing psychedelic medicines to treat addiction, have signed a referral agreement... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company ") is pleased to announce that the Company has entered into a definitive agreement dated June 15, 2021 (the " Agreement ") with Lobo Genetics Inc. (" Lobo "), and 13089363 Canada Inc. (" Subco "), a wholly-owned subsidiary of Entheon. Pursuant to the Agreement, Entheon and Lobo will combine their respective businesses by way of a... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced its Psychedelics Genetic Test Kit, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc. ("HaluGen"), is now available for sale in the United States. The Psychedelics Genetic Test Kit, a first of its kind, was designed... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the " Agreement ") with Laboratorium Ofichem BV (" Ofichem " or "Ofichem Group" ). Under the terms of the Agreement, Ofichem will supply Entheon with GMP quality N,N-dimethyltryptamine... Read More

Launch of Psychedelics DNA Test Kit Phase 1 clinical trial for DMT progressing as planned Pre-clinical In Vivo work scheduled to start at Israeli CRO Strengthened expertise focused on driving initiatives forward Upgraded OTC Listing Financial Update Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTCQB: ENTBF) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat... Read More

Entheon Biomedical Corp. (CSE: ENBI) today announced that, Timothy Ko, CEO of Entheon, will be attending the Q2 Virtual Investor Summit. Event Q2 Investor Summit Date May 17-18th, 2021 Presentation May 17th at 10:15 AM ET Location https://zoom.us/webinar/register/WN_qt5qaIR9SyODcSgsjZOfqw About Entheon Biomedical Corp. Entheon Biomedical is a drug development and biotechnology company whose primary aim is to provide... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: "1XU1") (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has been approved for trading on the OTCQB Venture Market ("OTCQB") effective May 5, 2021. "We are thrilled to be up-listing on to the OTCQB, which will allow for greater engagement with our U.S. investor... Read More

Microdose Psychedelic Insights ("Microdose"), the leader in B2B psychedelic intelligence, in partnership with The Conscious Fund , the most active VC fund in the psychedelic space, is pleased to present the next edition of Psychedelic Capital . #PsyCap is taking place on March 31 at 1:30pm EST and will feature engaging presentations from Entheon Biomedical Corp . (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) , Mind Cure Health... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce Nancy Maher as Special Advisor of Data Science and Regulatory Affairs, providing expertise on the development of the Company's data strategy design, study design and advise on regulatory relationships and data... Read More

Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides a production update on HaluGen Life Sciences Inc. (" HaluGen "), a wholly-owned subsidiary of Entheon, which is in the business of developing and commercializing a genetic test designed to identify specific DNA biomarkers in order to gauge the risk... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced ethics approval for an upcoming pre-clinical study to be conducted by the clinical research organization, Science in Action, an Israeli-based lab specializing in pre-clinical in vivo and in vitro R&D services. Science in Action has... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Dr. Brian Jahns to the role of Chief Business Officer. Dr. Jahns brings more than 20 years of business leadership and biopharmaceutical expertise to his role in overseeing the overall business... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTC PINK: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Jonna Birgans, a highly experienced media executive and producer, as Vice President of Digital Experience. Mrs. Birgans' significant depth of experience spans wide across the media and... Read More

Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ( "Entheon" or the "Company" ), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides an update on license amendments issued to its clinical research organization, The Centre for Human Drug Research (CHDR). Entheon confirms that the CHDR, the Company's Netherlands-based partner clinical research organization, has... Read More